Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)
1 Views
administrator
07/14/23
Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
-
Category
Show more
Facebook Comments
No comments found